TRINITY BIOTECH PLC
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $61.6M | $56.8M | $62.5M | $81.1M | $102.0M | $90.4M | $97.0M | $99.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — |
| Operating Income | $-21.2M | $-27.0M | $-19.3M | $3.9M | $82.0K | $-24.1M | $-20.2M | $-37.7M |
| Operating Margin | -34.4% | -47.6% | -30.9% | 4.9% | 0.1% | -26.7% | -20.8% | -38.0% |
| Interest Expense | — | — | — | — | $6.8M | $6.6M | $5.1M | $5.4M |
| Pretax Income | $-30.7M | $-36.9M | $-43.8M | $-1.9M | $-6.6M | $-30.0M | $-23.2M | $-39.9M |
| Income Tax Expense | $486.0K | $-59.0K | $-194.0K | $-74.0K | $-620.0K | $-1.0M | $-525.0K | $-1.2M |
| Net Income | $-31.8M | $-24.0M | $-41.0M | $875.0K | $-6.4M | $-28.9M | $-22.1M | $-40.3M |
| Net Margin | -51.6% | -42.3% | -65.6% | 1.1% | -6.3% | -32.0% | -22.8% | -40.6% |
| EPS (Basic) | — | — | — | — | — | — | — | — |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 359.2M | 153.3M | 152.4M | 83.6M | 83.6M | 83.6M | 96.2M | 96.2M |
| Shares Outstanding (Diluted) | 359.2M | 153.3M | 152.4M | 83.6M | 83.6M | 83.6M | 96.2M | 96.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |